Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a 
Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that 
is being developed by Immunomedics for the treatment of solid tumours, including 
breast cancer. In April 2020, sacituzumab govitecan received accelerated 
approval in the USA for the treatment of adult patients with metastatic 
triple-negative breast cancer (mTNBC) who have received at least two prior 
therapies for metastatic disease. Sacituzumab govitecan is undergoing phase III 
development for breast cancer in the USA and EU, and phase II development for 
urothelial cancer. It is also being explored for brain metastases, glioblastoma, 
endometrial cancer and prostate cancer. This article summarizes the milestones 
in the development of sacituzumab govitecan leading to this first approval for 
mTNBC.